ARGX
ARGX clinical trials: ARGENX SE
Every trial on ClinicalTrials.gov where ARGENX SE is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 100
- Trials linked
- 87
- As lead sponsor
- 13
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
ARGX on the catalyst calendar · ARGX registry changes
- Primary completion Jul 28, 2028Sponsor estimatePhase 2NCT07760818A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory...argenx · Sjogrens DiseaseRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2026ActualPhase 4NCT06909214A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)argenx · New Onset Generalized Myasthenia Gravis (gMG)RecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 2NCT07673627ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With...argenx · AChR-Ab Seropositive Generalized Myasthenia GravisRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2028Sponsor estimatePhase 1NCT07610564A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathyargenx · Multifocal Motor Neuropathy (MMN)RecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2029Sponsor estimatePhase 2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in...argenx · Spinal Muscular Atrophy (SMA)RecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 2/Phase 3NCT07194850A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)argenx · Immune Thrombocytopenia (ITP)RecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2027Sponsor estimatePhase 3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx · Chronic Inflammatory Demyelinating PolyneuropathyRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx · Chronic Inflammatory Demyelinating PolyneuropathyRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2034Sponsor estimateNo phase registeredNCT06298565A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfaargenx · Myasthenia GravisRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 2/Phase 3NCT07638566A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With...argenx · Chronic Inflammatory Demyelinating PolyradiculoneuropathyWithdrawnARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimateNo phase registeredNCT06078553A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4argenx · Congenital Myasthenic SyndromeActive, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07596849A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.argenx · Graves DiseaseRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 3NCT07570316A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Diseaseargenx · Graves' DiseaseRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimateNo phase registeredNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx · Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT06284954A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositisargenx · DermatomyositisActive, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimateNo phase registeredNCT05988073A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathyargenx · Multifocal Motor NeuropathyActive, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimatePhase 2/Phase 3NCT05374590Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children...argenx · Generalized Myasthenia GravisEnrolling by invitationARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 2NCT04280718A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory...argenx · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Active, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2/Phase 3NCT04833894Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized...argenx · Generalized Myasthenia GravisActive, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2NCT07821762A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndromeargenx · Guillain-Barré Syndrome (GBS)Not yet recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2029Sponsor estimatePhase 2NCT07773727A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANargenx · Immunoglobulin A Nephropathy (IgAN)RecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 7, 2028Sponsor estimateNo phase registeredNCT07294170ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With...argenx · Myasthenia GravisRecruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2030Sponsor estimatePhase 3NCT07746089A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital...argenx · Congenital Myasthenic SyndromeNot yet recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT06655155A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosisargenx · Systemic Sclerosis (SSc)Active, not recruitingARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT05979441A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic...argenx · MyositisEnrolling by invitationARGXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 75 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner